Ligand Pharmaceuticals Incorporated (NASDAQ:LGND – Get Free Report) CFO Octavio Espinoza sold 5,000 shares of the firm’s stock in a transaction dated Tuesday, March 4th. The stock was sold at an average price of $115.03, for a total value of $575,150.00. Following the completion of the sale, the chief financial officer now directly owns 18,879 shares of the company’s stock, valued at approximately $2,171,651.37. This represents a 20.94 % decrease in their position. The sale was disclosed in a filing with the SEC, which is available at this link.
Octavio Espinoza also recently made the following trade(s):
- On Monday, December 23rd, Octavio Espinoza sold 2,104 shares of Ligand Pharmaceuticals stock. The stock was sold at an average price of $116.37, for a total value of $244,842.48.
Ligand Pharmaceuticals Trading Down 1.0 %
Shares of LGND stock opened at $114.83 on Friday. The stock has a 50 day moving average of $114.26 and a 200 day moving average of $111.51. The stock has a market cap of $2.21 billion, a P/E ratio of 45.75 and a beta of 1.12. Ligand Pharmaceuticals Incorporated has a twelve month low of $67.72 and a twelve month high of $129.90.
Institutional Inflows and Outflows
Wall Street Analyst Weigh In
Several equities research analysts have weighed in on LGND shares. Barclays raised their price target on Ligand Pharmaceuticals from $150.00 to $160.00 and gave the stock an “overweight” rating in a report on Monday, December 16th. Royal Bank of Canada raised their price objective on Ligand Pharmaceuticals from $141.00 to $143.00 and gave the stock an “outperform” rating in a research note on Wednesday, December 11th. Benchmark restated a “buy” rating and issued a $135.00 price objective on shares of Ligand Pharmaceuticals in a research note on Monday, December 23rd. HC Wainwright restated a “buy” rating on shares of Ligand Pharmaceuticals in a research note on Wednesday, December 11th. Finally, Oppenheimer raised their price objective on Ligand Pharmaceuticals from $135.00 to $147.00 and gave the stock an “outperform” rating in a research note on Friday, November 8th. Six analysts have rated the stock with a buy rating, According to data from MarketBeat, the stock presently has an average rating of “Buy” and an average target price of $147.00.
Get Our Latest Stock Report on Ligand Pharmaceuticals
Ligand Pharmaceuticals Company Profile
Ligand Pharmaceuticals Incorporated, a biopharmaceutical company, engages in the development and licensing of biopharmaceutical assets worldwide. Its commercial programs include Kyprolis and Evomela, which are used to treat multiple myeloma; Rylaze, a recombinant erwinia asparaginase for the treatment of acute lymphoblastic leukemia or lymphoblastic lymphoma in adult and pediatric patients; Filspari, a dual endothelin and angiotensin II receptor antagonist in development for rare kidney diseases and non-immunosuppressive treatment indicated for immunoglobulin A nephropathy; Teriparatide injection product for osteoporosis; Vaxneuvance for the prevention of invasive disease caused by streptococcus pneumoniae serotypes; and Pneumosil, a pneumococcal conjugate vaccine to help fight against pneumococcal pneumonia among children.
Further Reading
- Five stocks we like better than Ligand Pharmaceuticals
- How to Know if a Stock Pays Dividends and When They Are Paid Out
- Is Myers Industries Poised for a Breakout?
- How to trade penny stocks: A step-by-step guide
- Is BigBear.ai’s 25% Plunge a False Alarm or Fire Sale?
- What is a buyback in stocks? A comprehensive guide for investors
- Broadcom Confirmed Its AI Outlook: Stock to Hit New Highs Soon
Receive News & Ratings for Ligand Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ligand Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.